Partner, SV Health Investors’ Dementia Discovery Fund (DDF)

Christian Jung, PhD is a Partner at SV Health Investors, co-leading the Dementia Discovery Fund (DDF). He currently represents the fund on the Boards of Amphista Therapeutics Ltd., Harness Therapeutics Ltd., Leal Therapeuctics LLC and LoQus23 Therapeutics Ltd. Prior to joining SV, Christian held roles with Wellington Partners Life Sciences and High-Tech Gründerfonds (HTGF), Europe’s leading seed fund with €2bn under management. There, Christian structured and completed the seed- and early-stage investments in 9 life sciences companies, including Amal Therapeutics SA (acquired by Boehringer Ingelheim in 2019 for up to €325m), Cunesoft GmbH (acquired by Phlexglobal in 2020 for an undisclosed amount) and Rigontec GmbH (acquired by MSD in 2017 for up to €464m).